Salarius grants $225K transaction bonus to Acting CEO Rosenblum tied to Decoy merger

Decoy Therapeutics Inc.

Board approved $225,000 cash bonus for Acting CEO/CFO Mark J. Rosenblum.
Bonus payable upon closing of the previously announced merger with Decoy Therapeutics.
Payment subject to Rosenblum's continued employment through the closing date.
Rosenblum holds dual roles as Acting CEO and Executive VP/CFO.

item 5.02

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001615219-25-000148
form_type: 8-K
ticker: DCOY
cik: 0001615219
company_name: Decoy Therapeutics Inc.
filed_at: 2025-10-21T23:59:59+00:00
discovered_at: 2026-05-14T18:02:39.926565+00:00
generated_at: 2026-05-17T03:02:10.646213+00:00
sec_items: ["5.02"]
event_type: other_material
sentiment: neutral
materiality_score: 0.3
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001615219-25-000148
json_url: https://secwatch.observer/filing/0001615219-25-000148.json
markdown_url: https://secwatch.observer/filing/0001615219-25-000148.md
text_url: https://secwatch.observer/filing/0001615219-25-000148.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1615219/000161521925000148/0001615219-25-000148-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1615219/000161521925000148/flks-20251021.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001615219-25-000148

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.